Advancements and Applications of Lateral Flow Assays (LFAs): A Comprehensive Review

Area of Science:

• Biomedical Engineering
• Diagnostic Technologies
• Point-of-Care Testing

Background:

• The World Health Organization (WHO) established ASSURED criteria for diagnostic assay development over a decade ago.
• Lateral flow assays (LFAs) have evolved significantly, meeting these standards and integrating advanced technologies like AI and nanotechnology.
• LFAs have demonstrated broad utility, from infectious disease detection to cancer screening and environmental monitoring.

Purpose of the Study:

• To review the technological evolution of lateral flow assays (LFAs).
• To highlight the diverse applications of LFAs in various fields.
• To discuss future trajectories and challenges in LFA development and deployment.

Main Methods:

• Review of existing literature on lateral flow assay advancements.
• Analysis of technological integrations such as nanotechnology and artificial intelligence (AI).
• Examination of LFA performance metrics, including limit of detection (LOD) and specificity.

Main Results:

• Nanoparticle-enhanced LFAs achieve LODs as low as 0.01 pg/mL, a 100-fold improvement.
• AI algorithms reduce interpretation errors by 40% in low-contrast conditions.
• Over 3 billion COVID-19 antigen tests deployed globally showed 98% specificity; cancer screening LFAs show 92% concordance with gold standards.

Conclusions:

• LFAs are crucial for democratizing diagnostics due to their affordability, sensitivity, and user-friendliness.
• Ongoing innovations in materials, manufacturing, and multiplexing promise further improvements in scalability and cost-effectiveness.
• Addressing challenges in sensitivity, LOD, scalability, and reproducibility is key for future LFA development.